Complete Story


NEW indication Announcement for ABRAXANE for injectable Suspension (paclitaxel protein-bound particles for injectable suspension)(albumin-bound)

Celgene Corporation has announced that ABRAXANE is now approved for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy. READ MORE